MedTrace Logo

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

NCT04701021 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-07-08

No results posted yet for this study

Summary

This is a phase I, dose selection study of safety and effect of different doses of TENDU vaccine, a therapeutic peptide conjugate vaccine, in patients with relapse after primary radical prostatectomy.

Conditions

Interventions

BIOLOGICAL

TENDU

The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.

Sponsors & Collaborators

  • Ultimovacs ASA

    lead INDUSTRY

Principal Investigators

  • Wolfgang Lilleby, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-17
Primary Completion
2023-08-16
Completion
2023-08-16

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04701021 on ClinicalTrials.gov